Semuloparin
Alternative Names: AVE5026; Mulsevo; Octaparin; Octaparine; Semuloparin sodium; VisamerinLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Anticoagulants; Antithrombotics; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Submission Withdrawal Thromboembolism
Most Recent Events
- 20 Jul 2012 Discontinued - Phase-II for Thromboembolism (prevention; children and adolescents with a central venous line) in Hungary (SC)
- 20 Jul 2012 Discontinued - Phase-II for Thromboembolism (prevention; children and adolescents with a central venous line) in Singapore (SC)
- 09 Jul 2012 Regulatory submission withdrawn for Thromboembolism (prevention in patients receiving chemotherapy) in European Union (SC)